Metsera, Inc. (NASDAQ: MTSR) announced today that its lead injectable candidate MET‑097i achieved a placebo‑subtracted mean weight loss of up to 14.1% after 28 weeks in the VESPER‑1 Phase 2b trial, with no plateau and a 2.9% study discontinuation rate.
The company also reported interim tolerability data from VESPER‑3, showing a minimal diarrhea signal and a risk difference from placebo of 13% for nausea and 11% for vomiting after 12 weeks of two titration steps, indicating class‑leading tolerability for a fully biased, ultra‑long‑acting GLP‑1 receptor agonist.
With 239 participants in VESPER‑1 and 268 in VESPER‑3, the trials support rapid transition into a global Phase 3 program slated for late 2025, positioning MET‑097i as a first‑and best‑in‑class monthly‑dosing obesity therapy that could address unmet needs in the rapidly growing NuSH market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.